Hutchinson-Gilford Progeria Syndrome (HGPS) Global Market Report 2025
상품코드:1826939
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
허친슨-길포드 조로증(HGPS) 시장 규모는 최근 몇 년 동안 강력하게 성장하고 있습니다. 2024년 976억 3,000만 달러에서 2025년에는 1,062억 5,000만 달러에 달하고, CAGR 8.8%를 나타낼 전망입니다. 실적기간의 성장은 희소유전성 질환에 대한 의식 증가, 조로증 연구에 대한 자금 제공 증가, 유전자 검사의 확대, 희소질환에 대한 정부의 이니셔티브 증가, 유전성 질환의 세계적 유병률의 상승에 기인하고 있습니다.
허친슨-길포드 조로증(HGPS) 시장 규모는 향후 몇 년간 강력한 성장이 예상됩니다. 2029년에는 연평균 복합 성장률(CAGR) 8.6%를 나타내 1,478억 8,000만 달러로 성장할 전망입니다. 예측기간의 성장은 새로운 치료법의 연구개발 자금 증가, 조로증 유병률 증가, 세계 건강 관리 지출 증가, 신규 치료 접근법 채택 증가, 조기 진단에 대한 수요 증가로 인한 것입니다. 예측 기간의 주요 동향으로는 기술 진보, 표적 요법 개발, 차세대 시퀀싱(NGS) 기술 진보, 바이오마커 개발, 약물전달 시스템의 진보 등이 있습니다.
허친슨-길포드 조로증(HGPS)은 일반적으로 프로제리아로 알려져 있으며, 어린이의 급속한 노화를 일으키는 매우 드물고 치명적인 유전자 질환입니다. LMNA 유전자의 변이가 방아쇠가 되어, 성장 지연, 탈모, 피부의 조기 주름, 심혈관계 합병증 등의 증상을 일으킵니다. 조로증 환자의 평균 수명은 약 14.5년입니다.
허친슨-길포드 조로증(HGPS)의 주요 치료법은 파르네실 트랜스퍼라제 억제제(조킨비(로나파르닙) 등), 저용량 아스피린, 물리치료, 작업요법, 보청기, 유전 상담, 기타 지지요법 등입니다. 조킨비(로나파르닙)와 같은 파르네실 트랜스퍼라제 억제제는 단백질의 변형에 관여하는 효소를 억제함으로써 작용하고, 아동의 조기 노화를 지연시킬 수 있는 표적 치료를 제공합니다. 이러한 치료는 안티센스 올리고뉴클레오티드, CRISPR-Cas9 유전자 편집, RNA 간섭, 표적 약물 전달 시스템 등의 메커니즘을 이용하며, 경구, 주사, 정맥 내, 경피 등 다양한 방식으로 투여됩니다. 이 치료는 병원, 전문 클리닉, 학술 및 연구 기관 및 기타 의료시설과 같은 여러 건강 관리 환경에서 사용됩니다.
2025년 봄 미국 관세의 급상승과 이에 따른 무역 마찰은 의료 분야, 특히 필수적인 의료기기, 진단 장비 및 의약품 공급에 큰 영향을 미쳤습니다. 병원과 건강 관리 제공업체는 수입되는 수술 기구, 영상 진단 시스템, 주사기 및 카테터와 같은 소모품의 비용 상승에 시달리고 있으며, 그 대부분은 국내 대체품이 제한되어 있습니다. 이러한 비용 상승이 의료 예산을 압박하기 때문에 일부 의료기관은 장비 업그레이드를 늦추거나 비용 증가를 환자에게 전가하고 있습니다. 게다가 원료와 부품에 대한 관세는 중요한 의약품과 의료기기의 제조에 지장을 주고 공급망의 지연으로 이어지고 있습니다. 이에 비해 업계는 다양한 조달 전략을 채택하고 가능한 한 현지 생산을 확대하고 중요한 의료 제품의 관세 면제를 수행하고 있습니다.
이 조사 보고서는 허친슨-길포드 조로증(HGPS) 업계 세계 시장 규모, 지역 점유율, 허친슨-길포드 조로증(HGPS) 시장 점유율을 가진 경쟁 업체, 상세한 허친슨-길포드 조로증(HGPS) 시장 부문, 시장 동향, 비즈니스 기회 등 허친슨-길포드 조로증(HGPS) 시장 통계를 제공하는 The Business Research Company의 신간 보고서 시리즈 중 하나입니다. 이 허친슨-길포드 조로증(HGPS) 시장 조사 보고서는 업계의 현재 및 미래 시나리오를 자세히 분석하고 필요한 모든 것을 완벽한 관점에서 제공합니다.
향후 5년간의 성장률 8.6%라고 하는 예측은 전회 예측으로부터 0.2%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 장벽은 네덜란드와 덴마크에서 공급되는 호나팔니브 및 기타 조로증 표적 치료제의 비용을 증가시키고, 희귀질환 치료를 지연시키고, 소아 전문 의료비를 상승시킴으로써 미국을 방해할 것으로 예측됩니다. 또한 상호관세나 무역마찰·제한의 격화에 의한 세계경제·무역에 대한 악영향에 의해 그 영향은 보다 광범위하게 미칠 것으로 보입니다.
새로운 치료법의 R&D 기금 증가는 허친슨-길포드 조로증(HGPS) 시장 성장을 이끌 것으로 예측됩니다. R&D 기금은 기술 혁신을 촉진하고 과학 지식을 개선하며 기술적 솔루션을 발전시키는 데 필요한 자원을 말합니다. 이러한 자금 증가는 혁신적인 치료에 대한 수요 증가와 의료 진보에 대한 정부의 지원과 같은 요인 때문입니다. 연구개발에 대한 투자 확대는 임상시험을 지원하고 신규 치료법의 개발을 촉진함으로써 허친슨-길포드 조로증(HGPS)에 대한 치료의 진보를 가속시킵니다. 또한 이 질병의 유전적 기원에 대한 이해를 추진하고, 적대적인 해결책의 창출을 가능하게 합니다. 예를 들어, 2024년 4월 영국 정부 기관인 국가통계청(ONS)은 2022년 영국 정부의 연구개발(R&D) 순지출이 2021년 140억 파운드(158억 8천만 달러)에서 10.5% 증가한 155억 파운드(175억 9천만 달러)에 달했다고 보고했습니다. 그 결과, R&D 자금 증가는 허친슨-길포드 조로증(HGPS) 시장 성장에 기여하고 있습니다.
허친슨-길포드 조로증(HGPS) 시장 주요 기업들은 치료 효과를 높이고 이환자의 질병 진행을 늦추기 위해 고급 파르네실 트랜스퍼라제 억제제의 개발을 선호하고 있습니다. 파르네실트랜스퍼라제 억제제는 단백질의 변형을 담당하는 효소인 파르네실트랜스퍼라제를 억제하는 약제로, 세포의 이상증식이나 노화를 막는 데 도움이 됩니다. 예를 들어 2022년 7월 미국 바이오의약품회사인 아이거 바이오파머슈티컬즈(Eiger BioPharmaceuticals)는 유럽 위원회에서 조킨비(Zokinvy)의 판매 승인을 취득했으며, 소아 및 청년 성인에서 허친슨-길포드 조로증(HGPS) 및 처리 부전성 프로젤로이드 라미노 파티(PL)에 대한 유럽 최초의 유일한 승인 치료제가 되었습니다. 경구 질환 변형제인 조킨비는 임상시험에서 사망위험을 72% 감소시켜 평균 4.3년의 연명효과를 보였습니다. 유럽 위원회의 집중 승인은 EU 회원 27개국 외에도 아이슬란드, 리히텐슈타인, 노르웨이에도 적용됩니다.
2024년 5월 미국의 바이오 의약품 회사 Sentynl Therapeutics, Inc.는 Eiger BioPharmaceuticals, Inc.에서 조킨비를 비공개 금액으로 인수했습니다. 이 인수로 Sentynl은 노화를 가속화하고 수명을 현저하게 줄이는 초희소 유전자 질환으로 고통받는 환자의 암멧 의료 요구에 대응하는 것을 목표로 합니다. 미국에 본사를 둔 바이오 의약품 회사인 Eiger BioPharmaceuticals, Inc.는 초기에 허친슨-길포드 조로증(HGPS)의 치료제로 조킨비(로나파르닙)를 개발했습니다.
허친슨-길포드 조로증(HGPS) 시장은 유전자 검사, 진단, 의약품 개발, 임상시험, 전문 의료, 치료, 환자 지원, 상담 서비스 등의 서비스를 제공하는 기업이 얻는 수익으로 구성됩니다. 시장 가치에는 서비스 제공업체가 판매하거나 서비스 제공에 포함된 관련 상품의 가치가 포함됩니다. 허친슨-길포드 조로증(HGPS) 시장에는 의약품, 유전자 검사 키트, 의료기기 및 모니터링 장비, 영양 보조 식품 및 특별 식료품, 이동 보조 기기 판매도 포함됩니다. 이 시장의 가치는 "Factory Gate"가치, 즉 다른 기업(다운스트림 제조업자, 도매업체, 유통업체, 소매업체 포함)이든 직접 최종 고객이든, 상품 제조자 또는 제조자가 판매한 상품의 가치입니다. 이 시장에서 상품의 가치에는 상품 제작자에 의해 판매되는 관련 서비스도 포함됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 허친슨-길포드 조로증(HGPS) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 허친슨-길포드 조로증(HGPS) 시장 : 성장률 분석
세계의 허친슨-길포드 조로증(HGPS) 시장 실적 : 규모와 성장(2019-2024년)
세계의 허친슨-길포드 조로증(HGPS) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 허친슨-길포드 조로증(HGPS) : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 허친슨-길포드 조로증(HGPS) 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
파네실트랜스퍼레이스 억제제(조킨비(로나파르닙))
저용량 아스피린
물리 및 작업 치료
보청기
유전 상담
기타 치료 유형
세계의 허친슨-길포드 조로증(HGPS) 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구
주사제
정맥주사
경피
세계의 허친슨-길포드 조로증(HGPS) 시장 : 작용 기전별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
안티센스 올리고뉴클레오티드
Crispr-cas9 유전자 편집
리보핵산(RNA) 간섭
표적 약물 전달 시스템
세계의 허친슨-길포드 조로증(HGPS) 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
학술 및 연구 기관
기타 최종 사용자
세계의 허친슨-길포드 조로증(HGPS) 시장 : 파네실트랜스퍼레이스 억제제(조킨비(로나파르닙)) 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
로나파르닙 단독 요법
타 약물 병용 요법
세계의 허친슨-길포드 조로증(HGPS) 시장 : 저용량 아스피린 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
심혈관 보호
항염증 치료
세계의 허친슨-길포드 조로증(HGPS) 시장 : 물리 및 작업 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
이동성 지원 및 재활
관절 및 뼈 건강 관리
일상 활동용 보조 장비
세계의 허친슨-길포드 조로증(HGPS) 시장 : 보청기 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
기존 보청기
골전도 보청기(BAHA)
인공 와우
세계의 허친슨-길포드 조로증(HGPS) 시장 : 유전 상담 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
가족 유전자 검사
유전적 위험 평가
산전 상담 및 지도
세계의 허친슨-길포드 조로증(HGPS) 시장 : 기타 치료 유형, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
줄기세포 치료
유전자 편집 및 치료
영양 지원 및 관리
제7장 지역별/국가별 분석
세계의 허친슨-길포드 조로증(HGPS) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 허친슨-길포드 조로증(HGPS) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
허친슨-길포드 조로증(HGPS) 시장 : 경쟁 구도
허친슨-길포드 조로증(HGPS) 시장 : 기업 프로파일
National Institutes of Health(NIH) : 개요, 제품 및 서비스, 전략 및 재무 분석
Mount Sinai : 개요, 제품 및 서비스, 전략 및 재무 분석
Johns Hopkins Hospital : 개요, 제품 및 서비스, 전략 및 재무 분석
Duke University : 개요, 제품 및 서비스, 전략 및 재무 분석
Mayo Foundation for Medical Education and Research : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Cleveland Clinic
Children's Hospital of Philadelphia
St. Jude Children's Research Hospital
Cincinnati Children's Hospital Medical Center
University of Maryland
Boston Children's Hospital
Children's Hospital Los Angeles
Harvard Medical School
The Scripps Research Institute
Blueprint Genetics
Medicover Hospitals
Sentynl Therapeutics
UCSF Helen Diller Family Comprehensive Cancer Center
Progeria Research Foundation
AnGes MG Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
허친슨-길포드 조로증(HGPS) 시장(2029년) : 새로운 기회를 제공하는 국가
허친슨-길포드 조로증(HGPS) 시장(2029년) : 새로운 기회를 제공하는 부문
허친슨-길포드 조로증(HGPS) 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Hutchinson-Gilford Progeria Syndrome (HGPS), commonly known as progeria, is an extremely rare and fatal genetic condition that causes rapid aging in children. It is triggered by mutations in the LMNA gene, resulting in symptoms such as growth delays, hair loss, premature skin wrinkling, and cardiovascular complications. The average life expectancy of individuals with progeria is around 14.5 years.
The primary treatments for Hutchinson-Gilford Progeria Syndrome (HGPS) include farnesyltransferase inhibitors (such as Zokinvy (lonafarnib)), low-dose aspirin, physical and occupational therapy, hearing aids, genetic counseling, and other supportive therapies. Farnesyltransferase inhibitors such as Zokinvy (lonafarnib) work by blocking the enzyme responsible for protein modification, providing a targeted treatment that may help slow premature aging in affected children. These treatments are administered through various methods, including oral, injectable, intravenous, and transdermal routes, utilizing mechanisms such as antisense oligonucleotides, CRISPR-Cas9 gene editing, RNA interference, and targeted drug delivery systems. The treatment is utilized across multiple healthcare settings, including hospitals, specialty clinics, academic and research institutes, and other medical facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The hutchinson-gilford progeria syndrome (HGPS) market research report is one of a series of new reports from The Business Research Company that provides hutchinson-gilford progeria syndrome (HGPS) market statistics, including the hutchinson-gilford progeria syndrome (HGPS) industry global market size, regional shares, competitors with the hutchinson-gilford progeria syndrome (HGPS) market share, detailed hutchinson-gilford progeria syndrome (HGPS) market segments, market trends, and opportunities, and any further data you may need to thrive in the hutchinson-gilford progeria syndrome (HGPS) industry. This hutchinson-gilford progeria syndrome (HGPS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The hutchinson-gilford progeria syndrome (hgps) market size has grown strongly in recent years. It will grow from $97.63 billion in 2024 to $106.25 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to the rise in awareness about rare genetic disorders, increasing in funding for progeria research, expansion of genetic testing, rise in government initiatives for rare disease, and rise in global prevalence of genetic disorders.
The hutchinson-gilford progeria syndrome (hgps) market size is expected to see strong growth in the next few years. It will grow to $147.88 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to an increase in funding for research and development of new therapies, rising prevalence of progeria, increasing global healthcare expenditure, rising adoption of novel therapeutic approaches, and growing demand for early diagnosis. Major trends in the forecast period include technological advancements, development of targeted therapies, advancements in next-generation sequencing (NGS) technologies, development of biomarkers, and advancements in drug delivery systems.
The forecast of 8.6% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of lonafarnib and other progeria-targeting therapies sourced from the Netherlands and Denmark, thereby delaying rare disease treatment and elevating pediatric specialty care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rise in funding for research and development of new therapies is expected to drive the growth of the Hutchinson-Gilford Progeria Syndrome (HGPS) market. Research and development funding refers to financial resources allocated to fostering innovation, enhancing scientific knowledge, and advancing technological solutions. The increase in such funding is attributed to factors such as the growing demand for innovative treatments and government support for healthcare advancements. Greater investment in research and development accelerates progress in treating Hutchinson-Gilford Progeria Syndrome by supporting clinical trials and promoting the development of novel therapies. It also advances the understanding of the genetic origins of the disease and enables the creation of targeted solutions. For example, in April 2024, the Office for National Statistics, a UK-based government agency, reported that in 2022, the UK government's net expenditure on research and development (R&D) increased by 10.5%, reaching £15.5 billion ($17.59 billion), up from £14.0 billion ($15.88 billion) in 2021. As a result, increased funding for research and development is contributing to the growth of the Hutchinson-Gilford Progeria Syndrome (HGPS) market.
Leading companies in the Hutchinson-Gilford Progeria Syndrome (HGPS) market are prioritizing the development of advanced farnesyltransferase inhibitors to enhance treatment effectiveness and slow disease progression in affected patients. Farnesyltransferase inhibitors are drugs that block farnesyltransferase, an enzyme responsible for protein modification, helping prevent abnormal cell growth and aging. For instance, in July 2022, Eiger BioPharmaceuticals, a US-based biopharmaceutical company, received marketing authorization from the European Commission for Zokinvy, making it the first and only approved treatment in Europe for Hutchinson-Gilford Progeria Syndrome (HGPS) and processing-deficient progeroid laminopathies (PL) in children and young adults. Zokinvy, an oral disease-modifying agent, demonstrated a 72% reduction in mortality risk and an average life extension of 4.3 years in clinical trials. The European Commission's centralized authorization applies across all 27 EU member states as well as Iceland, Liechtenstein, and Norway.
In May 2024, Sentynl Therapeutics, Inc., a US-based biopharmaceutical company, acquired Zokinvy from Eiger BioPharmaceuticals, Inc. for an undisclosed amount. Through this acquisition, Sentynl aims to address the unmet medical needs of patients suffering from ultra-rare genetic conditions that cause accelerated aging and significantly shorten life expectancy. Eiger BioPharmaceuticals, Inc., a US-based biopharmaceutical company, originally developed Zokinvy (lonafarnib) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS).
Major players in the hutchinson-gilford progeria syndrome (hgps) market are National Institutes of Health (NIH), Mount Sinai, Johns Hopkins Hospital, Duke University, Mayo Foundation for Medical Education and Research, Cleveland Clinic, Children's Hospital of Philadelphia, St. Jude Children's Research Hospital, Cincinnati Children's Hospital Medical Center, University of Maryland, Boston Children's Hospital, Children's Hospital Los Angeles, Harvard Medical School, The Scripps Research Institute, Blueprint Genetics, Medicover Hospitals, Sentynl Therapeutics, UCSF Helen Diller Family Comprehensive Cancer Center, Progeria Research Foundation, AnGes MG Inc., and PRG Science & Technology Co. Ltd.
North America was the largest region in the hutchinson-gilford progeria syndrome (HGPS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hutchinson-gilford progeria syndrome (HGPS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the hutchinson-gilford progeria syndrome (HGPS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The hutchinson-gilford progeria syndrome (HGPS) market consists of revenues earned by entities by providing services such as genetic testing and diagnosis, drug development and clinical trials, specialized medical care and treatment, and patient support and counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hutchinson-gilford progeria syndrome (HGPS) market also includes sales of pharmaceutical drugs, genetic testing kits, medical devices and monitoring equipment, nutritional supplements and special diet products, and assistive mobility devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Hutchinson-Gilford Progeria Syndrome (HGPS) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on hutchinson-gilford progeria syndrome (hgps) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for hutchinson-gilford progeria syndrome (hgps) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hutchinson-gilford progeria syndrome (hgps) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment Type: Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)); Low-dose Aspirin; Physical And Occupational Therapy; Hearing Aids; Genetic Counseling; Other Treatment Types
2) By Route Of Administration: Oral; Injectable; Intravenous; Transdermal
3) By Mechanism Of Action: Antisense Oligonucleotides; Crispr-cas9 Gene Editing; Rna Interference; Targeted Drug Delivery Systems
4) By End-User: Hospitals; Specialty Clinics; Academic And Research Institutes; Other End-Users
Subsegments:
1) By Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)): Monotherapy With Lonafarnib; Combination Therapy With Other Drugs
2) By Low-dose Aspirin: Cardiovascular Protection; Anti-inflammatory Therapy
3) By Physical And Occupational Therapy: Mobility Support And Rehabilitation; Joint And Bone Health Management; Adaptive Equipment For Daily Activities
4) By Hearing Aids: Conventional Hearing Aids; Bone-Anchored Hearing Aids (BAHA); Cochlear Implants
5) By Genetic Counseling: Family Genetic Testing; Genetic Risk Assessment; Prenatal Counseling And Guidance
6) By Other Treatment Types: Stem Cell Therapy; Gene Editing and Therapy; Nutritional Support And Management
Companies Mentioned: National Institutes of Health (NIH); Mount Sinai; Johns Hopkins Hospital; Duke University; Mayo Foundation for Medical Education and Research; Cleveland Clinic; Children's Hospital of Philadelphia; St. Jude Children's Research Hospital; Cincinnati Children's Hospital Medical Center; University of Maryland; Boston Children's Hospital; Children's Hospital Los Angeles; Harvard Medical School; The Scripps Research Institute; Blueprint Genetics; Medicover Hospitals; Sentynl Therapeutics; UCSF Helen Diller Family Comprehensive Cancer Center; Progeria Research Foundation; AnGes MG Inc.; PRG Science & Technology Co. Ltd.
3. Hutchinson-Gilford Progeria Syndrome (HGPS) Market Trends And Strategies
4. Hutchinson-Gilford Progeria Syndrome (HGPS) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Growth Analysis And Strategic Analysis Framework
5.1. Global Hutchinson-Gilford Progeria Syndrome (HGPS) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market Growth Rate Analysis
5.4. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Total Addressable Market (TAM)
6.2. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
Intravenous
Transdermal
6.3. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antisense Oligonucleotides
Crispr-cas9 Gene Editing
Ribonucleic Acid (RNA) Interference
Targeted Drug Delivery Systems
6.4. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Academic And Research Institutes
Other End-Users
6.5. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Sub-Segmentation Of Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monotherapy With Lonafarnib
Combination Therapy With Other Drugs
6.6. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Sub-Segmentation Of Low-dose Aspirin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cardiovascular Protection
Anti-inflammatory Therapy
6.7. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Sub-Segmentation Of Physical And Occupational Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mobility Support And Rehabilitation
Joint And Bone Health Management
Adaptive Equipment For Daily Activities
6.8. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Sub-Segmentation Of Hearing Aids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Conventional Hearing Aids
Bone-Anchored Hearing Aids (BAHA)
Cochlear Implants
6.9. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Sub-Segmentation Of Genetic Counseling, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Family Genetic Testing
Genetic Risk Assessment
Prenatal Counseling And Guidance
6.10. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Stem Cell Therapy
Gene Editing and Therapy
Nutritional Support And Management
7. Hutchinson-Gilford Progeria Syndrome (HGPS) Market Regional And Country Analysis
7.1. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Hutchinson-Gilford Progeria Syndrome (HGPS) Market
9.1. China Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
9.2. China Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Hutchinson-Gilford Progeria Syndrome (HGPS) Market
10.1. India Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Hutchinson-Gilford Progeria Syndrome (HGPS) Market
11.1. Japan Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
11.2. Japan Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Hutchinson-Gilford Progeria Syndrome (HGPS) Market
12.1. Australia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Hutchinson-Gilford Progeria Syndrome (HGPS) Market
13.1. Indonesia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Hutchinson-Gilford Progeria Syndrome (HGPS) Market
14.1. South Korea Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
14.2. South Korea Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market
15.1. Western Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
15.2. Western Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Hutchinson-Gilford Progeria Syndrome (HGPS) Market
16.1. UK Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.1. Germany Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Hutchinson-Gilford Progeria Syndrome (HGPS) Market
18.1. France Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market
21.1. Eastern Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
21.2. Eastern Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Hutchinson-Gilford Progeria Syndrome (HGPS) Market
22.1. Russia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Hutchinson-Gilford Progeria Syndrome (HGPS) Market
23.1. North America Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
23.2. North America Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Hutchinson-Gilford Progeria Syndrome (HGPS) Market
24.1. USA Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
24.2. USA Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Hutchinson-Gilford Progeria Syndrome (HGPS) Market
26.1. South America Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
26.2. South America Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Hutchinson-Gilford Progeria Syndrome (HGPS) Market
27.1. Brazil Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Hutchinson-Gilford Progeria Syndrome (HGPS) Market
28.1. Middle East Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
28.2. Middle East Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Hutchinson-Gilford Progeria Syndrome (HGPS) Market
29.1. Africa Hutchinson-Gilford Progeria Syndrome (HGPS) Market Overview
29.2. Africa Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Hutchinson-Gilford Progeria Syndrome (HGPS) Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Hutchinson-Gilford Progeria Syndrome (HGPS) Market Competitive Landscape And Company Profiles
